

Haematologica
HAEMATOL/2018/199422
Version 3

Long-term follow-up of Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor

Andrea Biondi, Gunnar Cario, Paola De Lorenzo, Anders Castor, Valentino Conter, Veronica Leoni, Virginie Gandemer, Rob Pieters, Jan Stary, Gabriele Escherich, Myriam Campbell, Andishe Attarbaschi, Chi-Kong Li, Ajay Vora, Jutta Bradtke, Vaskar Saha, Maria Grazia Valsecchi, and Martin Schrappe

Disclosures: All authors declare that they have no conflicts of interest. Novartis provided the drug for the EsPhALL clinical study, and this project was partially funded by the grants listed below. The sponsors had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for decision to submit for publication.

Contributions: AB, MS, VS and MGV designed and planned the study. AB, VC, PDL, MGV and VL wrote the report. PDL oversaw data pooling, data checking, reporting, and analyses. MGV was the study statistician. AB, GC, AC, VG, RP, JS, GE, MC, AA, CKL, AV, SR, MS coordinated the clinical study in their own countries and were responsible for data in their group. All authors have revised and approved the final version of the report.